he technical knowledge of producing the Huaman Papilloma Virus (HPV) vaccine is among the most sophisticated in the world, which an Iranian company could fully achieve it. Clinical studies of the vaccine were started in July 2019; it was tested on healthy volunteers after passing quality-control tests and preclinical studies.
Containing proteins of HPV types 16 and 18, Papilloguard is a recombinant vaccine given to individuals 9 through 26 years of age to help protect against diseases caused by some types of Human Papilloma Virus (HPV).
After being approved for its effectiveness in increasing the antibody titer and its safety, the Iranian-made HPV vaccine received approval from the Food and Drug Organization of Iran to enter the market in the winter of 2020.
The research and development process of the product in laboratory and semi-industrial scales took three years.
The Director-General of the company has the capacity to produce 15 million doses of vaccine per year and can fully meet the needs of West Asia and North Africa.
Three Iranian Football Icons Attend the Opening Match of Asian Cup 2023
